HRP20100541T1 - Derivati bifeniloksioctene kiseline za liječenje respiratornih bolesti - Google Patents
Derivati bifeniloksioctene kiseline za liječenje respiratornih bolesti Download PDFInfo
- Publication number
- HRP20100541T1 HRP20100541T1 HR20100541T HRP20100541T HRP20100541T1 HR P20100541 T1 HRP20100541 T1 HR P20100541T1 HR 20100541 T HR20100541 T HR 20100541T HR P20100541 T HRP20100541 T HR P20100541T HR P20100541 T1 HRP20100541 T1 HR P20100541T1
- Authority
- HR
- Croatia
- Prior art keywords
- oxy
- biphenyl
- acetic acid
- sulfonyl
- halogen
- Prior art date
Links
- MAKUMOXHJKKTDP-UHFFFAOYSA-N 2-(2-phenylphenoxy)acetic acid Chemical class OC(=O)COC1=CC=CC=C1C1=CC=CC=C1 MAKUMOXHJKKTDP-UHFFFAOYSA-N 0.000 title description 2
- 208000023504 respiratory system disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 25
- 229910052736 halogen Inorganic materials 0.000 claims abstract 12
- 125000005843 halogen group Chemical group 0.000 claims abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 10
- 239000001257 hydrogen Substances 0.000 claims abstract 10
- 150000002367 halogens Chemical class 0.000 claims abstract 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract 8
- 150000002825 nitriles Chemical class 0.000 claims abstract 6
- 125000004429 atom Chemical group 0.000 claims abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract 2
- 125000003118 aryl group Chemical group 0.000 claims abstract 2
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 2
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 27
- -1 {5-Chloro-3'-fluoro-4'-[(4-fluorophenyl)sulfonyl]biphenyl-2-yl}oxy Chemical group 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- VNQMVQRNFMHTSY-ZDUSSCGKSA-N (2s)-2-[2-[4-(benzenesulfonyl)-2-chlorophenyl]-4-fluorophenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=C(F)C=C1C1=CC=C(S(=O)(=O)C=2C=CC=CC=2)C=C1Cl VNQMVQRNFMHTSY-ZDUSSCGKSA-N 0.000 claims 1
- RREARAFIZIMPPV-ZDUSSCGKSA-N (2s)-2-[2-[4-(benzenesulfonyl)-3-chlorophenyl]-4-fluorophenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=C(F)C=C1C1=CC=C(S(=O)(=O)C=2C=CC=CC=2)C(Cl)=C1 RREARAFIZIMPPV-ZDUSSCGKSA-N 0.000 claims 1
- KGLRJNVVYWUKAN-ZDUSSCGKSA-N (2s)-2-[2-[4-(benzenesulfonyl)-3-fluorophenyl]-4-fluorophenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=C(F)C=C1C1=CC=C(S(=O)(=O)C=2C=CC=CC=2)C(F)=C1 KGLRJNVVYWUKAN-ZDUSSCGKSA-N 0.000 claims 1
- GQWRODHBWFTHMM-LBPRGKRZSA-N (2s)-2-[4-chloro-2-[2-fluoro-4-(4-fluorophenyl)sulfonylphenyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=C(Cl)C=C1C1=CC=C(S(=O)(=O)C=2C=CC(F)=CC=2)C=C1F GQWRODHBWFTHMM-LBPRGKRZSA-N 0.000 claims 1
- SRGXJMZKXJIPJZ-ZDUSSCGKSA-N (2s)-2-[4-chloro-2-[4-(4-fluorophenyl)sulfonylphenyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=C(Cl)C=C1C1=CC=C(S(=O)(=O)C=2C=CC(F)=CC=2)C=C1 SRGXJMZKXJIPJZ-ZDUSSCGKSA-N 0.000 claims 1
- QUPFAUMGPXZZSQ-LBPRGKRZSA-N (2s)-2-[4-fluoro-2-[3-fluoro-4-(2-fluorophenyl)sulfonylphenyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=C(F)C=C1C1=CC=C(S(=O)(=O)C=2C(=CC=CC=2)F)C(F)=C1 QUPFAUMGPXZZSQ-LBPRGKRZSA-N 0.000 claims 1
- OJYRPSHAWFSTKU-LBPRGKRZSA-N (2s)-2-[4-fluoro-2-[3-fluoro-4-(3-fluorophenyl)sulfonylphenyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=C(F)C=C1C1=CC=C(S(=O)(=O)C=2C=C(F)C=CC=2)C(F)=C1 OJYRPSHAWFSTKU-LBPRGKRZSA-N 0.000 claims 1
- FJFSRGZFCYDEPR-ZDUSSCGKSA-N (2s)-2-[4-fluoro-2-[3-fluoro-4-(4-methoxyphenyl)sulfonylphenyl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1=CC=C(C=2C(=CC=C(F)C=2)O[C@@H](C)C(O)=O)C=C1F FJFSRGZFCYDEPR-ZDUSSCGKSA-N 0.000 claims 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- ISWSXSNHKLNPOG-UHFFFAOYSA-N 2-[2-[4-(benzenesulfonyl)-2-fluorophenyl]-4-chlorophenoxy]acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1C1=CC=C(S(=O)(=O)C=2C=CC=CC=2)C=C1F ISWSXSNHKLNPOG-UHFFFAOYSA-N 0.000 claims 1
- KROXGGPWHQTARO-UHFFFAOYSA-N 2-[2-[4-(benzenesulfonyl)-2-fluorophenyl]-4-fluorophenoxy]acetic acid Chemical compound OC(=O)COC1=CC=C(F)C=C1C1=CC=C(S(=O)(=O)C=2C=CC=CC=2)C=C1F KROXGGPWHQTARO-UHFFFAOYSA-N 0.000 claims 1
- TYRXLUSFQPXRFN-UHFFFAOYSA-N 2-[2-[4-(benzenesulfonyl)-3,5-difluorophenyl]-4-chlorophenoxy]acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1C1=CC(F)=C(S(=O)(=O)C=2C=CC=CC=2)C(F)=C1 TYRXLUSFQPXRFN-UHFFFAOYSA-N 0.000 claims 1
- KQASONHOPDYLTE-UHFFFAOYSA-N 2-[2-[4-(benzenesulfonyl)-3-(trifluoromethyl)phenyl]-4-fluorophenoxy]acetic acid Chemical compound OC(=O)COC1=CC=C(F)C=C1C1=CC=C(S(=O)(=O)C=2C=CC=CC=2)C(C(F)(F)F)=C1 KQASONHOPDYLTE-UHFFFAOYSA-N 0.000 claims 1
- XKSKEAXWWLKTNF-UHFFFAOYSA-N 2-[2-[4-(benzenesulfonyl)-3-fluorophenyl]-4-fluorophenoxy]acetic acid Chemical compound OC(=O)COC1=CC=C(F)C=C1C1=CC=C(S(=O)(=O)C=2C=CC=CC=2)C(F)=C1 XKSKEAXWWLKTNF-UHFFFAOYSA-N 0.000 claims 1
- ZXKZARMMAVBFRA-UHFFFAOYSA-N 2-[2-[4-(benzenesulfonyl)-3-fluorophenyl]-4-methylphenoxy]acetic acid Chemical compound CC1=CC=C(OCC(O)=O)C(C=2C=C(F)C(=CC=2)S(=O)(=O)C=2C=CC=CC=2)=C1 ZXKZARMMAVBFRA-UHFFFAOYSA-N 0.000 claims 1
- ZADWPVOZWHYYLG-UHFFFAOYSA-N 2-[2-[4-(benzenesulfonyl)phenyl]-4-chlorophenoxy]acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1C1=CC=C(S(=O)(=O)C=2C=CC=CC=2)C=C1 ZADWPVOZWHYYLG-UHFFFAOYSA-N 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
Abstract
Spoj formule (I) ili njegova farmaceutski prihvatljiva sol: naznačen time da: A i D su nezavisno izabrani iz vodika, halogena, nitrila, C1-3 alkila, C1-3 alkoksi, pri čemu zadnje 2 skupine mogu opcijski biti supstituirane sa jednim ili više atoma halogena; X je halogen ili C1-3 alkil koji je po potrebi supstituiran sa jednim ili više atoma halogena; Y je veza; Z je aril ili heteroaril po potrebi supstituiran sa jednim ili više atoma izabranih iz halogena, nitrila, C1-6 alkila, C1-6 alkoksi, SO2C1-6alkila, heteroarila; a zadnje četiri skupine mogu po potrebi biti supstituirane sa atomima halogena, nitrilom ili SO2C1-6alkilom; R1 i R2 nezavisno predstavljaju atom vodika ili C1-3 alkilnu skupinu; iliR1 i R2 zajedno mogu tvoriti 3-8-člani prsten koji po potrebi sadrži jedan ili više atoma izabranih iz O, S, NR3 i samog sebe, a koji su po potrebi supstituirani sa jednim ili više C1-C3 alkila; iR3 je vodik ili C1-C6 alkil. Patent sadrži još 21 patentni zahtjev.
Description
DERIVATI BIFENILOKSIOCTENE KISELINE ZA LIJEČENJE RESPIRATORNIH BOLESTI
Claims (22)
1. Spoj formule (I) ili njegova farmaceutski prihvatljiva sol:
[image]
naznačen time da:
A i D su nezavisno izabrani iz vodika, halogena, nitrila, C1-3 alkila, C1-3 alkoksi, pri čemu zadnje 2 skupine mogu opcijski biti supstituirane sa jednim ili više atoma halogena;
X je halogen ili C1-3 alkil koji je po potrebi supstituiran sa jednim ili više atoma halogena;
Y je veza;
Z je aril ili heteroaril po potrebi supstituiran sa jednim ili više atoma izabranih iz halogena, nitrila, C1-6 alkila, C1-6 alkoksi, SO2C1-6alkila, heteroarila; a zadnje četiri skupine mogu po potrebi biti supstituirane sa atomima halogena, nitrilom ili
SO2C1-6alkilom;
R1 i R2 nezavisno predstavljaju atom vodika ili C1-3 alkilnu skupinu;
ili
R1 i R2 zajedno mogu tvoriti 3-8-člani prsten koji po potrebi sadrži jedan ili više atoma izabranih iz O, S, NR3 i samog sebe, a koji su po potrebi supstituirani sa jednim ili više C1-C3 alkila; i
R3 je vodik ili C1-C6 alkil.
2. Spoj prema zahtjevu 1, naznačen time, da u njemu X je kloro, fluoro ili metil.
3. Spoj prema zahtjevu 1 ili 2, naznačen time, da se u njemu skupina SO2-Y-Z nalazi na poziciji 4 u fenilnom prstenu.
4. Spoj prema zahtjevu 1 ili 2, naznačen time, da se u njemu skupina SO2-Y-Z nalazi na poziciji 4 u fenilnom prstenu, orto u odnosu na obje skupine A i D.
5. Spoj prema zahtjevu 1 ili 2, naznačen time, da se u njemu skupina SO2-Y-Z nalazi na poziciji 4 u fenilnom prstenu, orto u odnosu na skupinu A i meta u odnosu na skupinu D.
6. Spoj prema bilo kojem od zahtjeva od 1 do 5, naznačen time, da su u njemu skupine A i D nezavisno vodik, halogen ili C1-3 alkil (posljednji je po potrebi supstituiran sa atomima halogena).
7. Spoj prema bilo kojem od zahtjeva od 1 do 6, naznačen time, da A je vodik, halogen ili CF3.
8. Spoj prema bilo kojem od zahtjeva od 1 do 7, naznačen time, da D je vodik, halogen ili metil.
9. Spoj prema bilo kojem od zahtjeva od 1 do 8, naznačen time, da su A i D nezavisno odabrani iz vodika i halogena.
10. Spoj prema bilo kojem od zahtjeva od 1 do 9, naznačen time, da R1 i R2 su nezavisno vodik ili C1-3 alkil.
11. Spoj prema bilo kojem od zahtjeva od 1 do 9, naznačen time, da R1 i R2 su nezavisno vodik ili metil.
12. Spoj prema bilo kojem od zahtjeva od 1 do 11, naznačen time, da Y je veza.
13. Spoj prema bilo kojem od zahtjeva od 1 do 12, naznačen time, da Z je fenil koji je po potrebi supstituiran sa halogenom ili C1-6 alkoksi.
14. Spoj prema bilo kojem od zahtjeva od 1 do 13, naznačen time, da Z je fenil koji je po potrebi supstituiran sa halogenom.
15. Spoj prema bilo kojem od zahtjeva od 1 do 14, naznačen time, da Z je fenil koji je po potrebi supstituiran sa fluoro.
16. Spoj formule (I) prema bilo kojem od zahtjeva od 1 do 15, naznačen time, da je odabran iz:
{[5-Kloro-4'-(fenilsulfonil)bifenil-2-il]oksi}octene kiseline;
{[3',5-Difluoro-4'-(fenilsulfonil)bifenil-2-il]oksi}octene kiseline;
(2S)-2-{[3',5-Difluoro-4'-(fenilsulfonil)bifenil-2-il]oksi}propanske kiseline;
({5-Kloro-3'-fluoro-4'-[(4-fluorofenil)sulfonil]bifenil-2-il}oksi)octene kiseline;
{[2',5-Difluoro-4'-(fenilsulfonil)bifenil-2-il]oksi}octene kiseline;
{[5-Kloro-2'-fluoro-4'-(fenilsulfonil)bifenil-2-il]oksi}octene kiseline;
{[5-fluoro-4'-(fenilsulfonil)-3'-(trifluorometil)bifenil-2-il]oksi}octene kiseline;
(2S)-2-({5-kloro-4'-[(4-fluorofenil)sulfonil]bifenil-2-il}oksi)propanske kiseline;
({5-kloro-2'-fluoro-4'-[(4-fluorofenil)sulfonil]bifenil-2-il}oksi)octene kiseline;
(2S)-2-({5-kloro-2'-fluoro-4'-[(4-fluorofenil)sulfonil]bifenil-2-il}oksi)propanske kiseline;
(2S)-2-({3',5-difluoro-4'-[(2-fluorofenil)sulfonil]bifenil-2-il}oksi)propanske kiseline;
(2S)-2-({3',5-difluoro-4'-[(4-metoksifenil)sulfonil]bifenil-2-il}oksi)propanske kiseline;
(2S)-2-({3',5-difluoro-4'-[(3-fluorofenil)sulfonil]bifenil-2-il}oksi)propanske kiseline;
({5-kloro-4'-[(4-fluorofenil)sulfonil]-2'-metilbifenil-2-il}oksi)octene kiseline;
(2S)-2-{[2'-kloro-5-fluoro-4'-(fenilsulfonil)bifenil-2-il]oksi}propanske kiseline;
({3'-fluoro-4'-[(4-fluorofenil)sulfonil]-5-metilbifenil-2-il}oksi)octene kiseline;
({5-kloro-4'-[(4-metoksifenil)sulfonil]bifenil-2-il}oksi)octene kiseline;
({4'-[(2-klorofenil)sulfonil]-3',5-difluorobifenil-2-il}oksi)octene kiseline;
(2S)-2-{[3'-kloro-5-fluoro-4'-(fenilsulfonil)bifenil-2-il]oksi}propanske kiseline;
({4'-[(3-klorofenil)sulfonil]-2',5-difluorobifenil-2-il}oksi)octene kiseline;
({2'-fluoro-4'-[(4-fluorofenil)sulfonil]-5-metilbifenil-2-il}oksi)octene kiseline;
{[3'-fluoro-5-metil-4'-(fenilsulfonil)bifenil-2-il]oksi}octene kiseline;
{[5-kloro-3',5'-difluoro-4'-(fenilsulfonil)bifenil-2-il]oksi}octene kiseline
i njegovih farmaceutski prihvatljivih soli.
17. Spoj formule (I) prema bilo kojem od zahtjeva od 1 do 15, naznačen time, da navedeni spoj je ({5-Kloro-3'-fluoro-4'-[(4-fluorofenil)sulfonil]bifenil-2-il}oksi)octena kiselina;
18. Spoj formule (I) prema bilo kojem od zahtjeva od 1 do 17, naznačen time, da je za upotrebu kod terapije.
19. Uporaba spoja formule (I), ili njegove farmaceutski prihvatljive soli, kao što je definirano u prethodnim zahtjevima, naznačena time, da se navedeni spoj koristi u proizvodnji lijeka za liječenje humanih bolesti ili stanja u kojima je korisna modulacija receptorske aktivnosti CRTh2.
20. Spoj, naznačen time, da ima formulu (II):
[image]
pri čemu R1, R2, A, D, X, Y i Z su definirani kao u zahtjevu 1, a R4 je C1-10 alkilna skupina.
21. Spoj, naznačen time, da ima formulu (III)
[image]
pri čemu A, D, X, Y i Z su definirani kao u zahtjevu 1.
22. Spoj, naznačen time, da ima formulu (V)
[image]
gdje R5, A, D, X, Y i Z su definirani kao u zahtjevu 1.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0520324A GB0520324D0 (en) | 2005-10-06 | 2005-10-06 | Novel compounds |
GB0525082A GB0525082D0 (en) | 2005-12-09 | 2005-12-09 | Novel compounds |
GB0602800A GB0602800D0 (en) | 2006-02-11 | 2006-02-11 | Novel Compounds |
PCT/GB2006/003697 WO2007039741A1 (en) | 2005-10-06 | 2006-10-05 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100541T1 true HRP20100541T1 (hr) | 2010-11-30 |
Family
ID=37564298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100541T HRP20100541T1 (hr) | 2005-10-06 | 2010-10-05 | Derivati bifeniloksioctene kiseline za liječenje respiratornih bolesti |
Country Status (26)
Country | Link |
---|---|
US (3) | US8008350B2 (hr) |
EP (1) | EP1937633B8 (hr) |
JP (1) | JP5114413B2 (hr) |
KR (1) | KR101275476B1 (hr) |
AR (1) | AR058077A1 (hr) |
AT (1) | ATE476414T1 (hr) |
AU (2) | AU2006298531B2 (hr) |
BR (1) | BRPI0616969A2 (hr) |
CA (1) | CA2624343A1 (hr) |
CY (1) | CY1110812T1 (hr) |
DE (1) | DE602006015984D1 (hr) |
DK (1) | DK1937633T3 (hr) |
EC (1) | ECSP088414A (hr) |
ES (1) | ES2347470T3 (hr) |
HR (1) | HRP20100541T1 (hr) |
IL (1) | IL190338A0 (hr) |
NO (1) | NO20082124L (hr) |
NZ (1) | NZ567070A (hr) |
PL (1) | PL1937633T3 (hr) |
PT (1) | PT1937633E (hr) |
RS (1) | RS51471B (hr) |
SA (1) | SA06270368B1 (hr) |
SI (1) | SI1937633T1 (hr) |
TW (1) | TW200745003A (hr) |
UY (1) | UY29839A1 (hr) |
WO (1) | WO2007039741A1 (hr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
SE0301009D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
KR100617852B1 (ko) | 2004-01-26 | 2006-08-28 | 삼성전자주식회사 | 엠펙-2 디코딩 시스템 및 그 동작 방법 |
GB0415320D0 (en) * | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
GB0418830D0 (en) | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
GB0422057D0 (en) * | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
EP1817282B1 (en) | 2004-11-23 | 2011-07-20 | AstraZeneca AB | Phenoxyacetic acid derivatives useful for treating respiratory diseases |
WO2006077425A1 (en) * | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors and further antitumor agents |
TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
EP1937632A1 (en) | 2005-10-06 | 2008-07-02 | Astra Zeneca AB | Novel compounds |
EP1948630A2 (en) * | 2005-11-05 | 2008-07-30 | AstraZeneca AB | Novel compounds |
JP2009519308A (ja) * | 2005-12-15 | 2009-05-14 | アストラゼネカ・アクチエボラーグ | 呼吸器疾患の処置のための置換ジフェニルエーテル、アミン、スルフィドおよびメタン |
HUE048024T2 (hu) * | 2006-08-10 | 2020-05-28 | Roy C Levitt | Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra |
UA100983C2 (ru) * | 2007-07-05 | 2013-02-25 | Астразенека Аб | Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты |
GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
CA2805452C (en) | 2010-07-05 | 2018-07-31 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
US20140328861A1 (en) | 2011-12-16 | 2014-11-06 | Atopix Therapeutics Limited | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis |
CN104011021B (zh) | 2011-12-21 | 2016-08-24 | 埃科特莱茵药品有限公司 | 杂环衍生物及其作为前列腺素d2受体调节剂的用途 |
WO2014006585A1 (en) | 2012-07-05 | 2014-01-09 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
JP6102637B2 (ja) * | 2013-08-22 | 2017-03-29 | Jsr株式会社 | 芳香族ジハライド化合物、重合体、重合体組成物及び成形体 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB690816A (en) | 1950-01-02 | 1953-04-29 | British Drug Houses Ltd | Improvements in or relating to the manufacture of substituted phenoxy acetic acids |
US3278524A (en) * | 1962-03-13 | 1966-10-11 | Beecham Group Ltd | Penicillins and their production |
CH432119A (de) | 1963-02-22 | 1967-03-15 | Geigy Ag J R | Verwendung von Halogen-o-hydroxy-diphenyläthern als antimikrobielle Mittel |
BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
DD113545A5 (hr) | 1973-03-30 | 1975-06-12 | ||
JPS5239888B2 (hr) * | 1973-05-28 | 1977-10-07 | ||
US3954852A (en) | 1973-10-19 | 1976-05-04 | Merck & Co., Inc. | Indenylacetic acid compounds |
CH582476A5 (hr) | 1973-10-29 | 1976-12-15 | Ciba Geigy Ag | |
CA1041531A (en) * | 1973-10-29 | 1978-10-31 | Eisai Co. Ltd. | M-phenoxyphenyl propionic acid derivatives and preparation thereof |
GB1585963A (en) | 1976-10-14 | 1981-03-11 | Lilly Industries Ltd | Aryl sulphur compounds |
US4248618A (en) * | 1977-05-06 | 1981-02-03 | Ici Australia Limited | Derivatives of (pyrimidyloxy)phenoxy-alkanecarboxylic acid and herbicidal compositions thereof |
FR2428629A1 (fr) * | 1978-06-14 | 1980-01-11 | Hexachimie | Nouveaux composes bis(aryloxycarboxyliques), leur preparation et leur utilisation en therapeutique |
JPS5951943B2 (ja) | 1978-08-21 | 1984-12-17 | キツセイ薬品工業株式会社 | 新規なイミダゾ−ル誘導体 |
GB2041363B (en) | 1979-01-19 | 1982-10-06 | Pfizer Ltd | N-benzyl-imidazoles |
US4670566A (en) * | 1979-07-12 | 1987-06-02 | A. H. Robins Company, Incorporated | 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones |
US4486593A (en) | 1983-01-19 | 1984-12-04 | The Upjohn Company | 2-,3-, or 4-Pyridinylmethylamino arylic acids as thromboxane A2 synthetase and 5-lipoxygenase inhibitors |
US5006542A (en) * | 1988-10-31 | 1991-04-09 | E. R. Squibb & Sons, Inc. | Arylthioalkylphenyl carboxylic acids, derivatives thereof, compositions containing same and method of use |
US5145790A (en) * | 1990-05-04 | 1992-09-08 | Abbott Laboratories | Reagents and method for detecting polychlorinated biphenyls |
EP0540165A1 (en) | 1991-10-03 | 1993-05-05 | Zeneca Limited | Alkanoic acid derivatives |
WO1993012086A1 (en) | 1991-12-11 | 1993-06-24 | Ss Pharmaceutical Co., Ltd. | Arylamide derivative |
CA2090283A1 (en) * | 1992-02-28 | 1993-08-29 | Nobuyuki Hamanaka | Phenoxyacetic acid derivatives |
ES2156120T3 (es) * | 1992-12-08 | 2001-06-16 | Ss Pharmaceutical Co | Derivados arilamidicos. |
JPH06313995A (ja) * | 1993-04-28 | 1994-11-08 | Hodogaya Chem Co Ltd | 静電荷像現像用トナー |
EP0622816B1 (en) | 1993-04-30 | 1998-07-22 | Kabushiki Kaisha Meidensha | Electrode and process for forming an electrode material |
JPH07140725A (ja) | 1993-06-25 | 1995-06-02 | Hodogaya Chem Co Ltd | 負帯電性トナー用摩擦帯電付与部材 |
BR9610207A (pt) | 1995-08-28 | 1999-02-02 | American Home Prod | Acidos fenóxi acéticos como inibidores da aldose redutase e agentes anti-hiperglicêmicos |
DE19544828A1 (de) | 1995-12-01 | 1997-06-05 | Hoechst Ag | Hochmolekulare Copolymere |
CN1230884A (zh) | 1996-07-22 | 1999-10-06 | 孟山都公司 | 硫羟砜金属蛋白酶抑制剂 |
EP0839808A1 (en) | 1996-10-29 | 1998-05-06 | Novartis AG | Pyrazole derivatives, processes for their preparation, and their use as herbicides |
FR2763588B1 (fr) * | 1997-05-23 | 1999-07-09 | Cird Galderma | Composes triaromatiques, compositions les contenant et utilisations |
CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
US5942532A (en) | 1997-09-05 | 1999-08-24 | Ortho Pharmaceutical Corporation | 2-substituted phenyl-benzimidazole antibacterial agents |
DE69825603T2 (de) | 1997-09-12 | 2005-07-28 | Merck Frosst Canada & Co, Kirkland | 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2 |
WO1999019291A1 (fr) * | 1997-10-14 | 1999-04-22 | Asahi Kasei Kogyo Kabushiki Kaisha | Derives de biphenyl-5-acide alcanoique et leurs applications |
EP1211513B1 (en) | 1999-08-23 | 2006-01-04 | BML, Inc. | Method of identifying modulators of prostaglandin d2 receptors |
DK1206457T3 (da) | 1999-08-27 | 2004-02-16 | Lilly Co Eli | Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER |
JP2003523336A (ja) | 2000-02-18 | 2003-08-05 | メルク エンド カムパニー インコーポレーテッド | 糖尿病及び脂質障害のためのアリールオキシ酢酸 |
WO2001081312A2 (en) | 2000-04-24 | 2001-11-01 | Merck Frosst Canada & Co. | Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore |
KR20030013433A (ko) | 2000-05-31 | 2003-02-14 | 아스트라제네카 아베 | 혈관 손상 활성을 가진 인돌 유도체 |
US6699997B2 (en) * | 2000-06-28 | 2004-03-02 | Teva Pharmaceutical Industries Ltd. | Carvedilol |
US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
US20040097555A1 (en) * | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
BR0210391A (pt) * | 2001-06-12 | 2004-06-15 | Elan Pharm Inc | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto |
BR0307406A (pt) | 2002-02-01 | 2004-12-28 | Hoffmann La Roche | Indóis substituìdos como agonistas alfa-1 |
SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
WO2003068744A1 (fr) | 2002-02-18 | 2003-08-21 | Ishihara Sangyo Kaisha, Ltd. | Derives de la pyridine ou leurs sels, et inhibiteurs de production de citokine renfermant ces derives |
KR20050008661A (ko) * | 2002-03-20 | 2005-01-21 | 메타볼렉스, 인코포레이티드 | 치환된 페닐아세트산 |
AU2003231509A1 (en) | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Compound exhibiting pgd 2 receptor antagonism |
WO2003097042A1 (fr) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Antagoniste de recepteur de pdg2 |
SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
PE20040844A1 (es) | 2002-11-26 | 2004-12-30 | Novartis Ag | Acidos fenilaceticos y derivados como inhibidores de la cox-2 |
ZA200505523B (en) * | 2002-12-20 | 2006-09-27 | Amgen Inc | Asthma and allergic inflammation modulators |
CN1768040A (zh) | 2003-03-28 | 2006-05-03 | 伊莱利利公司 | 作为akt(蛋白激酶b)抑制剂的异喹啉-5-磺酸酰胺 |
SE0301009D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
DE60303238T2 (de) | 2003-04-25 | 2006-09-14 | Actimis Pharmaceuticals, Inc., La Jolla | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten |
SA04250253B1 (ar) * | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
US7166738B2 (en) * | 2004-04-23 | 2007-01-23 | Roche Palo Alto Llc | Non-nucleoside reverse transcriptase inhibitors |
GB0409921D0 (en) * | 2004-05-04 | 2004-06-09 | Novartis Ag | Organic compounds |
BRPI0511676A (pt) | 2004-05-29 | 2008-01-08 | 7Tm Pharma As | uso medicinal de ligandos receptores |
GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
GB0418830D0 (en) * | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
GB0422057D0 (en) | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
EP1817282B1 (en) | 2004-11-23 | 2011-07-20 | AstraZeneca AB | Phenoxyacetic acid derivatives useful for treating respiratory diseases |
GB0510584D0 (en) | 2005-05-24 | 2005-06-29 | Novartis Ag | Organic compounds |
TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
EP1937632A1 (en) | 2005-10-06 | 2008-07-02 | Astra Zeneca AB | Novel compounds |
EP1948630A2 (en) * | 2005-11-05 | 2008-07-30 | AstraZeneca AB | Novel compounds |
JP4872318B2 (ja) | 2005-11-16 | 2012-02-08 | パナソニック株式会社 | 紙幣識別装置 |
JP2009519308A (ja) * | 2005-12-15 | 2009-05-14 | アストラゼネカ・アクチエボラーグ | 呼吸器疾患の処置のための置換ジフェニルエーテル、アミン、スルフィドおよびメタン |
UA100983C2 (ru) * | 2007-07-05 | 2013-02-25 | Астразенека Аб | Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты |
-
2006
- 2006-09-27 TW TW095135771A patent/TW200745003A/zh unknown
- 2006-10-04 UY UY29839A patent/UY29839A1/es not_active Application Discontinuation
- 2006-10-05 AU AU2006298531A patent/AU2006298531B2/en not_active Ceased
- 2006-10-05 RS RSP-2010/0432A patent/RS51471B/en unknown
- 2006-10-05 SI SI200630777T patent/SI1937633T1/sl unknown
- 2006-10-05 PT PT06794649T patent/PT1937633E/pt unknown
- 2006-10-05 WO PCT/GB2006/003697 patent/WO2007039741A1/en active Application Filing
- 2006-10-05 AR ARP060104385A patent/AR058077A1/es not_active Application Discontinuation
- 2006-10-05 US US12/089,276 patent/US8008350B2/en not_active Expired - Fee Related
- 2006-10-05 EP EP06794649A patent/EP1937633B8/en active Active
- 2006-10-05 AT AT06794649T patent/ATE476414T1/de active
- 2006-10-05 JP JP2008534073A patent/JP5114413B2/ja not_active Expired - Fee Related
- 2006-10-05 BR BRPI0616969-4A patent/BRPI0616969A2/pt not_active IP Right Cessation
- 2006-10-05 DK DK06794649.1T patent/DK1937633T3/da active
- 2006-10-05 DE DE602006015984T patent/DE602006015984D1/de active Active
- 2006-10-05 PL PL06794649T patent/PL1937633T3/pl unknown
- 2006-10-05 CA CA002624343A patent/CA2624343A1/en not_active Abandoned
- 2006-10-05 NZ NZ567070A patent/NZ567070A/en not_active IP Right Cessation
- 2006-10-05 ES ES06794649T patent/ES2347470T3/es active Active
- 2006-10-07 SA SA06270368A patent/SA06270368B1/ar unknown
-
2008
- 2008-03-20 IL IL190338A patent/IL190338A0/en unknown
- 2008-04-04 KR KR1020087008244A patent/KR101275476B1/ko not_active IP Right Cessation
- 2008-04-30 EC EC2008008414A patent/ECSP088414A/es unknown
- 2008-05-06 NO NO20082124A patent/NO20082124L/no not_active Application Discontinuation
-
2010
- 2010-10-05 HR HR20100541T patent/HRP20100541T1/hr unknown
- 2010-10-06 CY CY20101100891T patent/CY1110812T1/el unknown
- 2010-12-20 US US12/973,395 patent/US8349897B2/en not_active Expired - Fee Related
- 2010-12-22 AU AU2010257385A patent/AU2010257385C1/en not_active Ceased
-
2011
- 2011-12-21 US US13/333,006 patent/US8415394B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100541T1 (hr) | Derivati bifeniloksioctene kiseline za liječenje respiratornih bolesti | |
ES2491140T3 (es) | Derivados de flavona enantioméricamente puros para el tratamiento de trastornos proliferativos y procesos para su preparación | |
RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
JP2011519854A5 (hr) | ||
JP2019509276A5 (hr) | ||
HRP20171028T1 (hr) | Indolski i indazolski spojevi koji aktiviraju ampk | |
AR066043A1 (es) | Derivados de benzamida sustituida como inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa tipo 1(11betahsd1) | |
HRP20170638T1 (hr) | MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI | |
RS52191B (en) | TETRAHYDROCYCLOPENT (B) INDOLE UNITS AS MODULATORS OF ANDROGENIC RECEPTORS | |
JP2006522118A5 (hr) | ||
HRP20190668T1 (hr) | Tetrazolonom supstituirani dihidropiridinonski mgat2 inhibitori | |
ES2536200T3 (es) | Preparación de compuestos de tipo 1-(bencilo sustituido)-5-trifluorometil-2-(1H)piridona, sales de estos y sus aplicaciones | |
AR048859A1 (es) | Utilizacion de derivados de indazol carboxamidas para la preparacion de un medicamento destinado al tratamiento y a la prevencion del paludismo | |
JP2010528089A5 (hr) | ||
AR068846A1 (es) | Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer | |
AR089134A1 (es) | Arilos y heteroarilos biciclicos inhibidores de los canales de sodio | |
RU2006107653A (ru) | Связующее вспомогательное вещество и приготовленная на его основе таблетка в форме капли | |
RU2010103813A (ru) | Пиримидилциклопентаны как ингибиторы акт протеинкиназ | |
CA2521425A1 (en) | Substituted phenoxy-acetic acids | |
AR038834A1 (es) | Derivados de nicotinamida utiles como inhibidores de pde4; composiciones farmaceuticas que los contienen; proceso de preparacion del compuesto y uso del mismo para fabricar un farmaco | |
RS54165B1 (en) | NEW LIGANDS FOR THE ESTROGENIC RECEPTOR | |
PE20110285A1 (es) | Derivados de sulfonamidofenil propionamida como ligandos del receptor vaniloide del subtipo 1 | |
RU2008129641A (ru) | Ингибиторы ccr9 активности | |
UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
AR049577A1 (es) | Derivados de hidantoina, procesos para su preparacion, composiciones y su uso |